Prestige Consumer Healthcare - PBH Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PBH shares.
View PBH analyst ratings or view top-rated stocks.

5 analysts have issued 12-month target prices for Prestige Consumer Healthcare's stock. Their PBH share price forecasts range from $70.00 to $72.00. On average, they anticipate the company's share price to reach $71.00 in the next twelve months. This suggests a possible upside of 16.7% from the stock's current price.
View analysts price targets for PBH or view top-rated stocks among Wall Street analysts.

Prestige Consumer Healthcare's stock was trading at $62.60 at the beginning of the year. Since then, PBH shares have decreased by 2.8% and is now trading at $60.82.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our PBH earnings forecast.

Prestige Consumer Healthcare Inc. (NYSE:PBH) posted its quarterly earnings results on Thursday, February, 2nd. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $275.50 million for the quarter, compared to analyst estimates of $273.84 million. Prestige Consumer Healthcare had a net margin of 18.97% and a trailing twelve-month return on equity of 12.65%. The company's revenue for the quarter was up .4% on a year-over-year basis. During the same period in the prior year, the business posted $0.99 EPS.

Prestige Consumer Healthcare updated its FY 2023 earnings guidance on Thursday, February, 2nd. The company provided earnings per share (EPS) guidance of $4.18-$4.18 for the period, compared to the consensus earnings per share estimate of $4.20. The company issued revenue guidance of $1.12 billion-$1.12 billion, compared to the consensus revenue estimate of $1.12 billion.

8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (2.14%), Rice Hall James & Associates LLC (1.26%), Leeward Investments LLC MA (1.09%), Fisher Asset Management LLC (0.82%), Burney Co. (0.60%) and Ziegler Capital Management LLC (0.44%). Insiders that own company stock include Mary Beth Fritz and Ronald M Lombardi.
View institutional ownership trends.

Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PBH stock can currently be purchased for approximately $60.82.

Prestige Consumer Healthcare (NYSE:PBH) has a market capitalization of $3.02 billion and generates $1.09 billion in revenue each year. The company earns $205.38 million in net income (profit) each year or $4.17 on an earnings per share basis.

The company employs 505 workers across the globe.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The official website for the company is www.prestigebrands.com. The company can be reached via phone at (914) 524-6800, via email at irinquiries@prestigebrands.com, or via fax at 302-674-5266.